Guangzhou Tiannuo Biological Pharmaceutical Technology

Tiannuo Pharma is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the discovery and development of innovative antimicrobials. The company utilizes a proprietary multitargeting drug discovery platform to develop hybrid small molecules designed to overcome antibiotic resistance and improve therapeutic outcomes. Its lead candidate, TNP-2092, is a rifamycin-quinolone hybrid that concurrently targets bacterial RNA polymerase, DNA gyrase, and topoisomerase IV. Tiannuo is currently advancing TNP-2092 through Phase 3 clinical trials for Helicobacter pylori infection and Phase 2 trials for prosthetic joint infections and hepatic encephalopathy. The company's pipeline also includes TNP-2198, a dual-acting agent targeting anaerobic and microaerophilic bacterial infections.